Bio-Techne (TECH) | Stock Overview & Key Data
Bio-Techne Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: $135.96 on September 20, 2021
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Financial Highlights
Quarter Income Flow
Jun 30, 2025
Annual Income Flow
2025
Dividend Information
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Bio-Techne
TECH
|
9.07B Mid-cap | 3.75% | -9.08% | -13.92% | -20.94% | -16.56% | 6.78% | -37.73% | -51.28% | 86.91% | 161.27% | 281.12% |
|
Vertex
VRTX
|
109.45B Large-cap | -2.49% | -1.11% | -12.54% | -1.86% | -5.98% | 1.24% | 34.08% | 113.19% | 376.31% | 717.28% | 1,190.86% |
|
Regeneron
REGN
|
80.98B Large-cap | -5.03% | -15.02% | -23.79% | -18.77% | -22.36% | 25.39% | -16.92% | 20.10% | 53.41% | 959.24% | 4,557.42% |
|
Axsome Therapeutics
AXSM
|
9.51B Mid-cap | -5.14% | -0.69% | 33.53% | 56.35% | 24.33% | 122.97% | 216.35% | 282.39% | 2,961.10% | 2,485.23% | 2,485.23% |
|
Praxis Precision
PRAX
|
9.60B Mid-cap | -26.51% | -23.68% | -22.06% | 43.85% | -10.03% | 807.83% | 2,210.03% | 21.08% | -16.07% | -16.07% | -16.07% |
|
Vaxcyte
PCVX
|
8.82B Mid-cap | -5.37% | -18.93% | -23.49% | 6.09% | 2.07% | 58.20% | 1.32% | 134.81% | 96.56% | 96.56% | 96.56% |
Ownership & Short Interest
Calculate Your Bio-Techne Investment Returns
Long-Term Investment Performance Analysis
Bio-Techne stock price in May 2016 was $27.65, A $1,000.00 lump sum investment in Bio-Techne made 10 years ago would be worth approximately $1,839.06 today, representing a solid return of 83.91%. This translates to an annualized return (CAGR) of 6.28%.
10 Years Investment Scenario (May 2016 - Jun 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is TECH's 52-week high and low?
- In the last 52 weeks, Bio-Techne reached a high of $72.16 (on January 22, 2026) and a low of $43.20 (on May 18, 2026).
- What is the market cap and P/E ratio for TECH?
- Curious about Bio-Techne's size and valuation? Its market capitalization stands at 9.07B. When it comes to valuation, the P/E ratio (trailing twelve months) is 117.16, and the forward P/E (looking ahead) is 26.21.
- Does TECH pay dividends? If so, what's the yield?
- Yes, Bio-Techne is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 0.62%, and the company has paid an average of $0.32 per share annually over the past 3 years.
- Who are Bio-Techne's main competitors or similar companies to consider before investing?
When looking at Bio-Techne, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX109.45B Healthcare Biotechnology 1.24% 34.08% Regeneron
REGN80.98B Healthcare Biotechnology 25.39% -16.92% Axsome Therapeutics
AXSM9.51B Healthcare Biotechnology 122.97% 216.35% Praxis Precision
PRAX9.60B Healthcare Biotechnology 807.83% 2,210.03% Vaxcyte
PCVX8.82B Healthcare Biotechnology 58.20% 1.32% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Bio-Techne Corporation? (e.g., ROE, Debt/Equity)
- To get a sense of Bio-Techne's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 3.80%, the Debt to Equity ratio from the most recent quarter is 20.07, and its Gross Profit Margin stands at 62.72%.
- What is the recent revenue and earnings growth for TECH?
- Looking at Bio-Techne's growth, its revenue over the trailing twelve months (TTM) was $1B. Compared to the same quarter last year (YoY), quarterly revenue grew by -1.00%, and quarterly earnings saw a YoY growth of 13.60%.
- How much of TECH stock is held by insiders and institutions?
- Wondering who owns Bio-Techne stock? Company insiders (like executives and directors) hold about 0.28% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 102.89%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.